Shares of MannKind jumped 20 percent before the market opened Friday after the drugmaker said it had confirmed with federal regulators the design of two late-stage clinical trials for its inhaled insulin. The company focuses on developing treatments for diabetes and cancer. It has no products on the market, and Afrezza is its lead candidate. MannKind ( MNKD - news - people ) will conduct clinical trials for the fast-acting, meal-time insulin Afrezza on patients with Type 1 and Type 2 diabetes. After the market had closed Thursday, company officials said that they confirmed the protocols for both trials with the Food and Drug Administration, and they were encouraged to promptly start the studies.
